These results suggested that mutations in different KRAS codons may have different effects on the resistance of rectal cancer to nCRT and that the rectal cancers carrying TP53 and KRAS mutations have a lower opportunity to respond to nCRT compared with wild-type tumors [83,112]. This evidence concerns the gene TP53 and rectal cancer.